SCD and cancer: Other studies have supported our findings that inhibition of SCD1/FADS2 could induce cellular ROS by activating typical oxidative stress response pathways including terminal UPR signaling and IRE1/JNK signaling, and abrogate NRF2/Keap1 antioxidant activity in several cancers 50, 51.